Xvivo Perfusion AB (ST:XVIVO) — Market Cap & Net Worth
Market Cap & Net Worth: Xvivo Perfusion AB (XVIVO)
Xvivo Perfusion AB (ST:XVIVO) has a market capitalization of $916.61 Million (Skr8.52 Billion) as of June 17, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #9473 globally and #144 in its home market, demonstrating a -2.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xvivo Perfusion AB's stock price Skr270.40 by its total outstanding shares 31499470 (31.50 Million). Review XVIVO current and long-term liabilities to assess the company's total debt and financial obligations.
Xvivo Perfusion AB Market Cap History: 2015 to 2026
Xvivo Perfusion AB's market capitalization history from 2015 to 2026. Data shows growth from $198.31 Million to $916.61 Million (16.88% CAGR).
Xvivo Perfusion AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xvivo Perfusion AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.78x
Xvivo Perfusion AB's market cap is 0.78 times its annual revenue
Latest Price to Earnings (P/E) Ratio
25.14x
Xvivo Perfusion AB's market cap is 25.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $298.31 Million | $138.18 Million | $1.50 Million | 2.16x | 198.74x |
| 2017 | $318.65 Million | $148.34 Million | $6.26 Million | 2.15x | 50.90x |
| 2018 | $447.46 Million | $187.87 Million | $12.69 Million | 2.38x | 35.27x |
| 2019 | $576.27 Million | $220.84 Million | $4.94 Million | 2.61x | 116.68x |
| 2020 | $1.06 Billion | $179.86 Million | -$43.73 Million | 5.92x | N/A |
| 2021 | $944.07 Million | $258.39 Million | $8.15 Million | 3.65x | 115.81x |
| 2022 | $620.34 Million | $415.29 Million | $18.43 Million | 1.49x | 33.66x |
| 2023 | $1.12 Billion | $597.54 Million | $91.82 Million | 1.87x | 12.16x |
| 2024 | $1.66 Billion | $822.41 Million | $172.18 Million | 2.02x | 9.63x |
| 2025 | $632.55 Million | $812.16 Million | $25.16 Million | 0.78x | 25.14x |
Competitor Companies of XVIVO by Market Capitalization
Companies near Xvivo Perfusion AB in the global market cap rankings as of June 17, 2026.
Key companies related to Xvivo Perfusion AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #151 globally with a market cap of $154.19 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #205 globally with a market cap of $117.85 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #237 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #245 globally with a market cap of $103.20 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #151 | Abbott Laboratories | NYSE:ABT | $154.19 Billion | $88.67 |
| #205 | Stryker Corporation | NYSE:SYK | $117.85 Billion | $307.94 |
| #237 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #245 | Medtronic PLC | NYSE:MDT | $103.20 Billion | $80.38 |
Xvivo Perfusion AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Xvivo Perfusion AB's market cap moved from $198.31 Million to $ 916.61 Million, with a yearly change of 16.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr916.61 Million | +44.91% |
| 2025 | Skr632.55 Million | -61.84% |
| 2024 | Skr1.66 Billion | +48.41% |
| 2023 | Skr1.12 Billion | +80.05% |
| 2022 | Skr620.34 Million | -34.29% |
| 2021 | Skr944.07 Million | -11.31% |
| 2020 | Skr1.06 Billion | +84.71% |
| 2019 | Skr576.27 Million | +28.79% |
| 2018 | Skr447.46 Million | +40.43% |
| 2017 | Skr318.65 Million | +6.82% |
| 2016 | Skr298.31 Million | +50.43% |
| 2015 | Skr198.31 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Xvivo Perfusion AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $916.61 Million USD |
| MoneyControl | $916.61 Million USD |
| MarketWatch | $916.61 Million USD |
| marketcap.company | $916.61 Million USD |
| Reuters | $916.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more